An unconventional route for modifying pharmaceutically relevant molecules swaps an atom of carbon for one of nitrogen. The resulting derivatives might open up avenues of research in ...
Changing the FDA biosimilar interchangeability standards is a necessary but likely insufficient step to improve biosimilar competition in the US. In 2009, Congress created a regulatory pathway for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results